Drug Device Combination

Table Of Contents

1 INTRODUCTION
  1.1 Key take-aways 
  1.2 Report description
  1.3 Markets Covered
  1.4 Stakeholders

2 SUMMARY

3 MARKET OVERVIEW 
  3.1 Evolution of drug-device combination 
  3.2 Driving factors analysis for drug-device combination market
  3.3 Drivers
      3.3.1 Increased efficiency 
      3.3.2 Exploiting existing technologies 
      3.3.3 Accelerated approval process 
      3.3.4 Medical insurance coverage 
      3.3.5 Rising awareness 
  3.4 Restraints
      3.4.1 Issues involved in cross industry partnerships 
      3.4.2 Drug-device combination products are expensive 
      3.4.3 Jurisdiction issues 
      3.4.4 Fear of possible side-effects
  3.5 Opportunities
      3.5.1 Reduction in investment costs 
      3.5.2 Streamlining issues in partnerships 
      3.5.3 Reduction in the overall cost of treatment 
      3.5.4 Market participation by smaller companies

4 DRUG-DEVICE COMBINATION PRODUCTS
  4.1 Antimicrobial catheter
      4.1.1 Drivers 
            4.1.1.1 Reduced incidences of infection in intensive care 0units
            4.1.1.2 Over all cost reduction 
            4.1.1.3 Certain catheters are prone to infections 
            4.1.1.4 Reimbursement issues 
            4.1.1.5 Presence of big players in the antimicrobial catheters market 
            4.1.1.6 Awareness of antimicrobial agents used for coating on the catheters 
            4.1.1.7 Demand unaffected by the economic downturn
      4.1.2 Restraints
            4.1.2.1 Price constraints 
            4.1.2.2 Lack of awareness in developing countries implementation of standard solutions
      4.1.3 Key players & their recent developments 
      4.1.4 Urological catheters
            4.1.4.1 Drivers 
                    4.1.4.1.1 Prevention of several nosocomial infections 
                    4.1.4.1.2 Beneficial for women and baby boomers 
                    4.1.4.1.3 Reduced health care costs 
                    4.1.4.1.4 Increased applications 
            4.1.4.2 Restraints
                    4.1.4.2.1 Alternatives to prolonged catherization 
                    4.1.4.2.2 Reimbursement issues 
                    4.1.4.2.3 Key players and their recent developments
            4.1.4.3 Dialysis catheter
                    4.1.4.3.1 Key players and their recent developments
                    4.1.4.3.2 Hemodialysis catheters 
                    4.1.4.3.3 Peritoneal catheters
                              4.1.4.3.3.1 Drivers
            4.1.4.4 Urinary catheters
                    4.1.4.4.1 Drivers 
                    4.1.4.4.2 Key players and their recent developments 
                    4.1.4.4.3 Indwelling cathetersExternal catheter
                           4.1.4.4.3.1 Drivers & restraints
                              4.1.4.4.3.2 Key players & their recent developments
                    4.1.4.4.4 External catheter
      4.1.5 Cardiovascular catheters
            4.1.5.1 Drivers
                    4.1.5.1.1 Indispensability associated with these catheters 
                    4.1.5.1.2 Suitable in emergency operations 
                    4.1.5.1.3 Rising number of obesity aiding the growth of the procedures that use these products 
                    4.1.5.1.4 Interventional procedures have better success ratio
            4.1.5.2 Restraints
                    4.1.5.2.1 Usage avoided due to high cost and subsequent reimbursement issue 
                    4.1.5.2.2 Incidence of infections due to the use of non-antimicrobial coated catheter not known
                    4.1.5.2.3 Competition from new technologies & devices
            4.1.5.3 Opportunities
                    4.1.5.3.1 Awareness of surgeons 
                    4.1.5.3.2 Resolving reimbursement structure 
                    4.1.5.3.3 Decreasing prices 
      4.1.6 Oximetry catheters
            4.1.6.1 Drivers
                    4.1.6.1.1 Reduction in catheter related blood stream infections
                    4.1.6.1.2 Prolonged fight against micro organisms 
                    4.1.6.1.3 Overall cost of hospitalization will go down
                    4.1.6.1.4 Popularity of uncoated variant 
                    4.1.6.1.5 Key players and their recent developments
      4.1.7 Thermodilution catheters
            4.1.7.1 Drivers
                    4.1.7.1.1 Fatal infections are avoided 
                    4.1.7.1.2 Increased usage likely in near future 
                    4.1.7.1.3 Increasing complications of the heart
            4.1.7.2 Restraints
                    4.1.7.2.1 Uncoated thermodilution catheters are cheaper
                    4.1.7.2.2 Fear of resistance from microorganism strains
                    4.1.7.2.3 Innovations in pharmaceutical therapies
     4.1.8 Wound drainage catheters
           4.1.8.1 Drivers
                   4.1.8.1.1 Useful in several surgeries 
                   4.1.8.1.2 Protection from wide variety of micro organisms 
                   4.1.8.1.3 Elimination of the risk of nosocomial infections on the wound sites
           4.1.8.2 Restraints
                   4.1.7.2.1 Proper handling required
 4.2 Advanced Wound Care Products
     4.2.1 Drivers 
           4.2.1.1 Multiple advantages over conventional wound care products 
           4.2.1.2 Supports healing process of the skin 
           4.2.1.3 Advanced gel based products accelerate healing process 
           4.2.1.4 Prevention of bacterial colonization on sutures 
           4.2.1.5 Reduction in the cost of hospitalization 
           4.2.1.6 Less frequent change of dressings required 
     4.2.2 Restraints 
           4.2.2.1 Lack of product differentiation leading to price wars 
           4.2.2.2 Minimally invasive surgeries are stunting the demand of wound-care products
     4.2.3 Opportunities
           4.2.3.1 Focus on research 
           4.2.3.2 Raise awareness of the care providers 
           4.2.3.3 Specially developed wound dressing products
     4.2.4 Key players and their recent developments
     4.2.5 Antibiotic wound care
           4.2.5.1 Drivers
                   4.2.5.1.1 Treatment is conducive for wide range of patients
                   4.2.5.1.2 Low risk of infections as silver is an ingredient in the product 
                   4.2.5.1.3 Nanotechnology paves the way for improved formulations 
           4.2.5.2 Restraints
                   4.2.5.2.1 Cost constraint 
                   4.2.5.2.2 Reimbursement issues 
           4.2.5.3 Opportunities
                   4.2.5.3.1 Rising awareness about the risk of infections
                   4.2.5.3.2 Edification of medical practitioners 
                   4.2.5.3.3 Ageing baby boomers 
           4.2.5.4 Key players and their recent developments
 4.3 Bone Graft Substitutes
     4.3.1 Drivers 
           4.3.1.1 Shortage of donors 
           4.3.1.2 Substitutes satisfying ideal properties of bone 
           4.3.1.3 Virtual elimination of the risk of infection 
           4.3.1.4 Improved life expectancy 
           4.3.1.5 Increasing need for orthopedic procedures
     4.3.2 Restraints 
           4.3.2.1 ‘One size fits all’ approach not possible 
           4.3.2.2 Procedure not affordable for all
     4.3.3 Key players and their recent developments 
     4.3.4 Ceramic based bone graft substitute
           4.3.4.1 Drivers
                   4.3.4.1.1 Most popular bone graft substitutes 
                   4.3.4.1.2 Compatibility with new technology 
                   4.3.4.1.3 Risk of transference of fatal diseases eliminated
                   4.3.4.1.4 Availability in various forms gives wider choice for applications 
                   4.3.4.1.5 Close proximity of composition to natural bone 
           4.3.4.2 Restraints
                   4.3.4.2.1 Stand alone ceramic products are brittle 
                   4.3.4.2.2 Application limited to non load bearing sites
                   4.3.4.2.3 Newer technology stunting the stand alone ceramics market
           4.3.4.3 Ceramic based bone graft substitutes mixed with calcium phosphate
                   4.3.4.3.1 Drivers 
                   4.3.4.3.2 Restraints 
                   4.3.4.3.3 Opportunities 
                   4.3.4.3.4 Key players and their recent developments 
           4.3.4.4 Allograft based bone graft substitutes
                   4.3.4.4.1 Drivers 
                             4.3.4.4.1.1 Totally natural enables faster healing 
                             4.3.4.4.1.2 Wide array of choice for various applications
                             4.3.4.4.1.3 Extraction of DBM helps in spine fusion 
                             4.3.4.4.1.4 Localized application of DBM enables faster healing 
                   4.3.4.4.2 Restraints 
                             4.3.4.4.2.1 Risk of disease diffusion not entirely eliminated
                             4.3.4.4.2.2 Success depends on the site of application 
                   4.3.4.4.3 Opportunities 
                             4.3.4.4.3.1 Wider adoption of new technology
                   4.3.4.4.4 Key players and their recent developments
           4.3.4.5 Factor based bone graft substitute
                   4.3.4.5.1 Drivers 
                             4.3.4.5.1.1 Cellular activity made possible in the bone
                             4.3.4.5.1.2 Removal of risks of toxicity 
                             4.3.4.5.1.3 Availability of supporting technology 
                   4.3.4.5.2 Restraints 
                             4.3.4.5.2.1 Several products yet to receive marketing approval
                             4.3.4.5.2.2 No guaranteed results 
                             4.3.4.5.2.3 Production process incurs high cost 
                   4.3.4.5.3 Opportunities
                             4.3.4.5.3.1 Effectiveness in treating spinal fusion 
                             4.3.4.5.3.2 More ‘factors’ to boost the market
                   4.3.4.5.4 Key players and their recent developments
           4.3.4.6 Cell based bone graft substitutes
                   4.3.4.6.1 Drivers 
                             4.3.4.6.1.1 Most adaptive to human body among all bone graft substitute variants 
                             4.3.4.6.1.2 Faster healing 
                             4.3.4.6.1.3 Simple process of extraction 
                   4.3.4.6.2 Restraints 
                             4.3.4.6.2.1 Limited results in practice 
                             4.3.4.6.2.2 Supporting technologies not available 
                             4.3.4.6.2.3 Several regulatory issues yet to be resolved 
                   4.3.4.6.3 Opportunities
                             4.3.4.6.3.1 Successful results 
                             4.3.4.6.3.2 Advancement in supporting technologies
                   4.3.4.6.4 Key players and their recent developments
 4.4 Antibiotic Bone Cements
     4.4.1 Drivers 
           4.4.1.1 Faster healing because of localized treatment 
           4.4.1.2 Prevention of infections 
     4.4.2 Restraints  
           4.4.2.1 Low bacterial resistance 
           4.4.2.2 Prone to allergic reactions 
           4.4.2.3 Expensive
     4.4.3 Key players and their recent developments 
 4.5 Drug Eluting Stents
     4.5.1 Drivers 
           4.5.1.1 Increased life expectancy 
           4.5.1.2 Interventional procedures have higher effectiveness
           4.5.1.3 Global acceptance of drug eluting stent technologies
           4.5.1.4 Reduces the need for repeat procedures 
     4.5.2 Restraints  
           4.5.2.1 Risk of clots for some patients 
           4.5.2.2 Adoption of better cholesterol fighting drugs 
           4.5.2.3 Bare metal stents cheaper than drug eluting  stents 
     4.5.3 Opportunities
           4.5.3.1 FDA’s support for drug eluting stents 
           4.5.3.2 New generation drug eluting stent
     4.5.4 Key players and their recent developments 
     4.5.5 Coronary stents  
           4.5.5.1 Drivers
                   4.5.5.1.1 Growing popularity of minimally invasive surgery
                   4.5.5.1.2 Prevention of reblockage 
                   4.5.5.1.3 Reduced instances of deathsby heart attacks
                   4.5.5.1.4 Diminished need for repeated procedures 
                   4.5.5.1.5 Obesity and other factors driving cardiac related issues
                   4.5.5.2 Restraints
                           4.5.5.2.1 Limited applications 
                           4.5.5.2.2 ‘Off-label’ applications 
                           4.5.5.2.3 Increased restrictions following controversy 
                           4.5.5.2.4 Possibility of side effects due to drug therapy following surgery 
           4.5.5.3 Opportunities
                   4.5.5.3.1 Possibility of increased applications 
                   4.5.5.3.2 Supporting technology reduces the risk of in-stent late thrombosis
           4.5.5.4 Key players and their recent developments
     4.5.6 Peripheral vascular stent
           4.5.6.1 Drivers
                   4.5.6.1.1 Alleviation of pain in the aged population 
                   4.5.6.1.2 Severe results are eliminated 
                   4.5.6.1.3 Prevalence of cigarette smoking acts as a driver 
           4.5.6.2 Restraints
                   4.5.6.2.1 Limited data available due to ignorance of the disease 
                   4.5.6.2.2 Lack of awareness of physicians 
           4.5.6.3 Key players and their recent developments
 4.6 Photodynamic Therapy
     4.6.1 Drivers 
           4.6.1.1 Localized treatment increases the effect of the therapy
           4.6.1.2 Less time gap between consumption of drug and light treatment
           4.6.1.3 Advantages over antibiotics 
           4.6.1.4 Treatment is inexpensive 
     4.6.2 Restraints 
           4.6.2.1 Competition from traditional treatments 
           4.6.2.2 Side effects 
     4.6.3 Opportunities
           4.6.3.1 Advanced research will help to treat larger solid tumors
           4.6.3.2 Promising field of non invasive anti tumor therapy
     4.6.4 Key players and their recent developments 
     4.6.5 Aminolevulinic acid
           4.6.5.1 Drivers
                   4.6.5.1.1 Accuracy in treatment 
                   4.6.5.1.2 Increase in potential size 
                   4.6.5.1.3 Increased potential in selected markets
                   4.6.5.1.4 Minimally invasive nature is attractive 
                   4.6.5.1.5 New avenues of treatment 
                   4.6.5.1.6 Cheaper than other alternatives
           4.6.5.2 Restraints
                   4.6.5.2.1 Application limited to selected areas of the body 
                   4.6.5.2.2 Prone to photosensitivity 
                   4.6.5.2.3 Other more efficient treatments are available
           4.6.5.3 Restraints
                   4.6.5.3.1 Application limited to certain geographical areas
                   4.6.5.3.2 Innovation will lead to better results 
     4.6.6 Porfimer sodium
           4.6.6.1 Drivers
                   4.6.6.1.1 A popular form of treatment
                   4.6.6.1.2 No long term side effects
                   4.6.6.1.3 Number of applications 
                   4.6.6.1.4 Treatment suitable for patients who do not qualify for other treatments 
           4.6.6.2 Restraints
                   4.6.6.2.1 Treatment is not independent 
                   4.6.6.2.2 Success depends upon the stage of the disease
                   4.6.6.2.3 Treatment eliminates extensive forms of cancer
                   4.6.6.2.4 Presence of side effects 
           4.6.5.3 Key players and their recent developments
     4.6.7 Verteporfin
           4.6.7.1 Drivers
                   4.6.7.1.1 Treats macular degeneration of the wet type 
                   4.6.7.1.2 Targeted treatment is effective on diseased area
           4.6.7.2 Restraints
                   4.6.7.2.1 Repeated procedures required 
                   4.6.7.2.2 New inventions in drug therapy 
                   4.6.7.2.3 Possible risk 
           4.6.7.3 Opportunities
                   4.6.7.3.1 Side effects associated with drug therapy 
                   4.6.7.3.2 New developments eliminate the need for repeat procedures
  4.7 Steroid Eluting Electrodes
      4.7.1 Drivers 
            4.7.1.1 Increasing demand for pacemakers and ICDs
            4.7.1.2 Continuously monitors the heart 
            4.7.1.3 Increased longevity 
      4.7.2 Restraints  
            4.7.2.1 Advantages of non steroid eluting electrodes 
            4.7.2.2 Monopoly by a few companies 
      4.7.3 Key players and their recent developments 
      4.7.4 Implantable cardioverter defibrillator
            4.7.4.1 Drivers
                    4.7.4.1.1 Prevention of inflammation 
                    4.7.4.1.2 Improved diagnosis of cardiac problem
            4.7.4.2 Restraints
                    4.7.4.2.1 Limited choice in product variety 
                    4.7.4.2.2 Restrained promotion about their effectiveness
      4.7.5 Deep brain stimulator
            4.7.5.1 Drivers
                    4.7.5.1.1 Treatment provides therapeutic benefits 
                    4.7.5.1.2 Varied applications
            4.7.5.2 Restraints
                    4.7.5.2.1 Fear of side effects
 4.8 Closed Loop Glucose Monitor and Insulin Pump
     4.8.1 Drivers 
           4.8.1.1 Minimal invasiveness leads to convenience 
           4.8.1.2 Hassle free diabetes management 
           4.8.1.3 Treatment made reliable 
           4.8.1.4 A killer disease 
           4.8.1.5 Monitoring of diabetes combating therapies 
           4.8.1.6 Monitoring of extreme levels of glucose 
           4.8.1.7 Insurance coverage 
     4.8.2 Restraints  
           4.8.2.1 Human intervention necessary 
           4.8.2.2 The combination product expensive 
           4.8.2.3 New technology 
     4.8.3 Opportunities
           4.8.3.1 Under penetration of the product in the U.S. 
           4.8.3.2 Further development of technology
     4.8.3 Key players and their recent developments 
 
5 DRUG-DEVICE COMBINATION APPLICATION
  5.1 Cardiovascular Treatment
      5.1.1 Drivers 
            5.1.1.1 Provide better treatment 
            5.1.1.2 Increasing number of cardiovascular treatments
            5.1.1.3 Increased comfort to the elderly 
            5.1.1.4 Diabetes patients with cardiovascular problems
      5.1.2 Restraints
            5.1.2.1 Restriction enforced by FDA 
            5.1.2.2 Post surgery medication adds up to the cost 
            5.1.2.3 Prevention of cardiovascular diseases
      5.1.3 Coronary angioplasty
            5.1.3.1 Drivers 
                    5.1.3.1.1 Reduced risk of sudden heart attacks 
                    5.1.3.1.2 Treatment independent of economic situation
            5.1.3.2 Restraints
                    5.1.3.2.1 Not recommended for angina 
                    5.1.3.2.2 Expensive nature of treatment
      5.1.4 Tachycardia management
            5.1.4.1 Drivers 
                    5.1.4.1.1 Reduced chances of heart failure 
                    5.1.4.1.2 Diagnosis has opened up new avenues
            5.1.4.2 Restraints
                    5.1.4.2.1 Unknown potential market size 
                    5.1.4.2.2 Lack of awareness
      5.1.5 Pediatric bradycardia
            5.1.5.1 Drivers 
            5.1.5.2 Restraints
 5.2 Non-Cardiovascular Treatments
     5.2.1 Drivers 
           5.2.1.1 Several new treatments for non-cardiovascular diseases
           5.2.1.2 Issue of reimbursement 
           5.2.1.3 Untapped markets 
           5.2.1.4 Reap full potential of present technologies
     5.2.2 Restraints 
           5.2.2.1 Partnership issues 
           5.2.2.2 Rising popularity of alternative therapies 
           5.2.2.3 Underlying cause of disease not known
     5.2.3 Peripheral arterial disease (PAD)
           5.2.3.1 Symptoms of the disease are often confused with general problems of old age
     5.2.4 Intravascular access
           5.2.4.1 Drivers 
                   5.2.4.1.1 Indispensable in modern day medical imstitutions
                   5.2.4.1.2 Prevents infection along with serving other purposes
                   5.2.4.1.3 Agents used to coat the catheters have already been tested 
                   5.2.4.1.4 New developments give increased mobility
           5.2.4.2 Restraints
                   5.2.4.2.1 Following guidelines for use of uncoated catheters eliminates need for coated ones 
                   5.2.4.2.2 Increasing minimally invasive surgeries
     5.2.5 Intravascular access
           5.2.5.1 Drivers 
                   5.2.5.1.1 New opportunities 
                   5.2.5.1.2 Large segment of population afflicted with the disease
 5.3 Urological Treatments
     5.3.1 Drivers 
           5.3.1.1 Wide array of applications 
           5.3.1.2 Various factors boost the market 
           5.3.1.3 Improved efficiency of new treatments
     5.3.2 Restraints 
           5.3.2.1 Urological diseases overshadowed by cardiovascular diseases
     5.3.3 Dialysis
           5.3.3.1 Drivers
                   5.3.3.1.1 High per capita revenue 
                   5.3.3.1.2 Reimbursement plans activated 
                   5.3.3.1.3 Convenience associated with home dialysis
           5.3.3.2 Restraints
     5.3.4 Urinary tract infections
           5.3.4.1 Drivers
                   5.3.4.1.1 Women prone to such infections 
                   5.3.4.1.2 Prevention better than cure
           5.3.4.2 Restraints
                   5.3.4.2.1 Diagnosing urinary tract infections is still an issue
 5.4 Bone Treatment
     5.4.1 Drivers 
           5.4.1.1 High success ratio to drive the market
           5.4.1.2 Degenerative diseases to push the market forward 
           5.4.1.3 Several factors are promoting their usage 
           5.4.1.4 Transmission of fatal diseases can be avoided
     5.4.2 Restraints
           5.4.2.1 Therapies are not of the same standard as allograft and autografts
     5.4.3 Joint arthroplasty
           5.4.3.1 Drivers 
                   5.4.3.1.1 Deep prosthetics infections reduced to 1.6% from 6%
                   5.4.3.1.2 Obesity increasing the demand for joint arthroplasty
                   5.4.3.1.3 Improved accuracy gives confidence to its application
           5.4.3.2 Restraints
                   5.4.3.2.1 Rising necessity of revision surgeries
     5.1.4 Spine fusion
 5.5 Antimicrobial Applications
     5.5.1 Drivers 
           5.5.1.1 Application is increasing over time 
           5.5.1.2 Rising number of diabetic patients 
           5.5.1.3 Infection prevention leads to faster recovery 
           5.5.1.4 Reduced expenditure incurred by hospitals
     5.5.2 Restraints 
           5.5.2.1 Lack of resources in urban safety-net hospitals 
           5.5.2.2 Developing countries have not adopted these treatments
     5.5.3 Wound care
           5.5.3.1 Drivers 
                   5.5.3.1.1 Several factors giving boost to the market 
                   5.5.3.1.2 Slowing down in demand is not possible
           5.5.3.2 Restraints
     5.5.4 Skin substitutes
           5.5.4.1 Drivers 
                   5.5.4.1.1 Infection risk is eliminated 
                   5.5.4.1.1 Faster healing reduces period of convalescence
           5.5.4.2 Restraints
                   5.5.4.2.1 Reimbursement issue is a restraining factor
 5.6 Cancer Treatment
     5.6.1 Drivers 
           5.6.1.1 Increase in the number of cancer patients 
           5.6.1.2 Treatment using PDT is non invasive and patient friendly 
           5.6.1.3 Risks associated with the treatment is minimal 
           5.6.1.4 Treatment without risk of side effects
     5.6.2 Restraints 
           5.6.2.1 Limited applications 
           5.6.2.2 Possibility of inadequate number of health care professionals 
           5.6.2.3 New pharmaceutical inventions
     5.6.3 Barrett’s esophagus
           5.6.3.1 Drivers
                   5.6.3.1.1 Increasing prevalence of the disease 
                   5.6.3.1.2 Several advantages of the treatment 
           5.6.3.2 Restraints
                   5.6.3.2.1 Improved efficiency of the treatment
     5.6.4 Skin cancer
           5.6.4.1 Drivers
                   5.6.4.1.1 Increased diagnosis of skin cancer cases will give a boost to the market 
                   5.6.4.1.2 Broadening variety of cancer patients 
                   5.6.4.1.3 Prevalence of such cancer in developed countries 
                   5.6.4.1.4 Application not limited to one disease 
           5.6.4.2 Restraints
                   5.6.4.2.1 Phototoxicity 
                   5.6.4.2.2 Limited market potential 
     5.6.5 Head and neck cancer
           5.6.5.1 Drivers
                   5.6.5.1.1 Preferred treatment in certain cases 
                   5.6.5.1.2 Less risk of long term infections
           5.6.5.2 Restraints
                   5.6.5.2.1 Patients revert to conventional treatments if cancer relapses 
                   5.6.5.2.2 Low success rate due to co morbidity
 5.7 Skin Care/Treatment
     5.7.1 Drivers 
           5.7.1.1 Increasing demand for skin care therapy
           5.7.1.2 Treatment is done at the inner dermis layer
     5.7.2 Restraints 
           5.7.2.1 Loyal customers of cosmetic companies 
           5.7.2.2 Limited marketing activities for PDT
     5.7.3 Opportunities
           5.7.3.1 Improved marketing activities
           5.7.3.2 Untapped potential in developing countries
     5.7.4 Actinic keratoses
           5.7.4.1 Drivers
                   5.7.4.1.1 High demand in the U.S. and Australia
                   5.7.4.1.2 Enhanced treatment
                   5.7.4.1.3 Elimination of risk of skin cancer
                   5.7.4.1.4 Added advantage of cosmetic enhancement
           5.7.4.2 Restraints
                   5.7.4.2.1 Demand is not global
                   5.7.4.2.2 Repeated procedures make the patients photosensitive
     5.7.5 Photorejuvenation
 5.8 Ophthalmic Treatment
     5.8.1 Drivers 
           5.8.1.1 Increased demand from the ageing population
           5.8.1.2 Offers physical and economical advantages
     5.8.2 Restraints 
           5.7.2.1 Repeated treatments required
     5.8.3 Pathologic myopia
           5.8.3.1 Drivers 
                   5.8.3.1.1 One of the leading causes of blindness in people of certain races
                   5.8.3.1.2 Photodynamic therapy is an alternative option
                   5.8.3.1.3 Increased preference by sportspersons
           5.8.3.2 Restraints
                   5.8.3.2.1 Repetetion of procedures will add to the cost
                   5.8.3.2.2 Preference of contact lenses over PDT
     5.8.4 Age related macular degeneration
           5.8.4.1 Drivers
                   5.8.4.1.1 Age related macular degeneration has the potential of becoming a national health issue
                   5.8.4.1.2 Non invasive nature leads to no pain and inconvenience
                   5.8.4.1.3 No damage to the retina
          5.8.4.2. Restraints
                   5.8.4.2.1 Success restricted by certain factors
                   5.8.4.2.2 Non recovery of normal 6/6 vision 
     5.8.5 Presumed ocular histoplasmosis
 5.9 Diabetes Treatment
     5.9.1 Drivers 
           5.9.1.1 Increasing number of diabetes patients
           5.9.1.2 Potential in middle income countries
           5.9.1.3 New generation treatments effective in diabetic patients
     5.9.2 Restraints 
           5.9.2.1 Possible restraining factors in future
           5.9.2.2 Limited opportunity in Africa
     5.9.3 Opportunities
           5.9.3.1 Obesity and increasing age of people
           5.9.3.2 Development in technologies will reduce the cost
 
6 DRUG-DEVICE COMBINATION MARKET BY TECHNOLOGY 
  6.1. Synthetic Bone Graft Substitutes
       6.1.1. Drivers 
              6.1.1.1. Availability of several types enables customized usage 
              6.1.1.2. Surgeons have several options
              6.1.1.3. Applicable in load bearing body parts 
              6.1.1.4. Foreign substance eliminated from the body
              6.1.1.5. Increased applications
       6.1.2. Restraints  
              6.1.2.1. Do not possess ideal properties
              6.1.2.2. Possible stunted growth in future
  6.2. Synthetic Bone Graft Substitutes
       6.1.1. Drivers 
              6.2.1.1. Easy to understand technology
              6.2.1.2. Applicable for different types of bone defects
              6.2.1.3. Growing number of aged people
       6.2.2. Restraints
              6.2.2.1. Lack of osteoinductive properties
              6.2.2.2. Competition from other procedures
  6.3. Bone Morphogenic Proteins 

7 GEOGRAPHY ANALYSIS 
  7.1. The U.S. Drug-device Combination Market  
  7.2. The European Drug-device Combination Market 
  7.3. The Asian Drug Device Combination Market

8 COMPANY PROFILES 
  8.1 3M
  8.2 ABBOTT LABORATORIES
  8.3 ACRYMED
  8.4 AGION TECHNOLOGIES, INC
  8.5 ALLOSOURCE
  8.6 ANGIOTECH PHARMACEUTICALS, INC
  8.7 APATECH
  8.8 ARROW INTERNATIONAL
  8.9 ATRIUM MEDICAL CORPORATION
  8.10 BIOMET ORTHOPEDICS, INC.
  8.11 BIOMETRIX MEDICAL
  8.12 BIOSENSORS
  8.13 BIOTRONIK
  8.14 BOSTON SCIENTIFIC CORPORATION
  8.15 C.R. BARD, INC.
  8.16 COLLAGEN MATRIX, INC.
  8.17 COOK CRITICAL CARE, INC.
  8.18 COOK MEDICAL
  8.19 CORDIS CORPORATION
  8.20 CORIN
  8.21 COVALON
  8.22 COVIDIEN LTD
  8.23 DAVOL INC.
  8.24 DEPUY ORTHOPAEDICS INC.
  8.25 DUSA PHARMACEUTICALS, INC.
  8.26 EDWARDS LIFESCIENCES CORP.
  8.27 ETEX
  8.28 ETHICON, INC.
  8.29 EXACTECH INC.
  8.30 FORTICELL BIOSCIENCE, INC.
  8.31 INTEGRA LIFESCIENCES HOLDINGS CORP.
  8.32 KIADIS PHARMA B.V.
  8.33 LIFECELL CORP
  8.34 MEDTRONIC, INC.
  8.35 NUCRYST PHARMACEUTICALS, INC.
  8.36 ORBUSNEICH CO., LTD.
  8.37 ORGANOGENESIS, INC
  8.38 OSTEOTECH, INC.
  8.39 QLT INC.
  8.40 SMITH & NEPHEW PLC
  8.41 SPIRE BIOMEDICAL INC.
  8.42 ST. JUDE MEDICAL INC
  8.43 STRYKER CORPORATION
  8.44 SUNGWON MEDICAL CO., LTD.
  8.45 SYNTHES, INC.
  8.46 TEI BIOSCIENCES, INC.
  8.47 VYGON S.A
  8.48 W.L. GORE & ASSOCIATES INC.
  8.49 WRIGHT MEDICAL GROUP, INC.
  8.50 XTENT
  8.51 ZIMMER HOLDING, INC.

9 PATENT ANALYSIS
  9.1. U.S. Patents
  9.2. E.U. Patents
  9.3. ASIA Patents

APPENDIX
 
LIST OF FIGURES

1 Parental structure of drug-combination market
2 Evolution of drug-device combination
3 Factors affecting the drug-device combination market
4 Current favorability for drug-device combination market
5 Market potential for drug-device combination market
6 Trends in r&d for drug-device combination market
7 Global market share of key players
8 Global segmentation of drug-device combination patents
 
LIST OF TABLES

1 Global antimicrobial catheter market, by products 2007 – 2014 ($Millions)
  1a Global antimicrobial catheter market, by thousands of units 2007 – 2014
2 Global antimicrobial catheter market, by geography 2007 – 2014 ($Millions)
3 Major players and product developments
4 Global urological catheter market, by products 2007 – 2014 ($Millions) 
  4a Global urological catheter market, by product by thousands of units 2007-2014
  4b Global urological catheter market, by polymers 2007 – 2014 ($Millions)
5 Global urological catheter market, by geography 2007 – 2014 ($Millions)
6 Major players and product developments
7 Global dialysis catheter market, by products 2007 – 2014 ($Millions)
  7a Global dialysis catheter market, by product by thousands of units 2007-2014
  7b Global dialysis catheter market, by polymers 2007 – 2014 ($Millions)
8 Global dialysis catheter market, by geography 2007 – 2014 ($Millions)
9 Major players and product developments
10 Global hemodialysis catheter market, by geography 2007 – 2014 ($Millions)
11 Global peritoneal catheter market, by geography, 2007 – 2014 ($Millions)
12 Global urinary catheter market, by products 2007 – 2014 ($Millions)
   12a Global urinary catheter market, by products, by thousands of units 2007-2014
   12b Global urinary catheter market, by polymers 2007 – 2014 ($Millions)
13 Global urinary catheter market, by geography 2007 – 2014 ($Millions)
14 Major players and product developments
15 Global indwelling catheter market, by geogrphy 2007 – 2014 ($Millions)
16 Major players and product developments
17 Global external catheter market, by geography 2007 – 2014 ($Millions)
18 Global oximetry catheter market, by products 2007 – 2014 ($Millions)
19 Global thermodilution catheter market by geography 2007 – 2014 ($Millions)
20 Major players and product developments
21 Global advanced wound care products market, by products 2007 – 2014 ($Millions)
   21a Global advanced wound care market, by product, by thousands of units 2007-2014
   21b Global advanced wound care market, by materials 0f construction 2007 – 2014 ($Millions)
22 Global advanced wound care products market, by geography 2007 – 2014 ($Millions)
23 Major players and product developments
24 Global antibiotic wound care market, by geography 2007 – 2014 ($Millions)
25 Major players and product developments
26 Global bone graft substitues market, by products 2007 – 2014 ($Millions)
27 Global bone graft substitues market, by geography 2007 – 2014 ($Millions)
28 Major players and product developments
29 Global ceramic based bone graft substitutes market, by products 2007 – 2014 ($Millions)
30 Global ceramic based bone graft substitutes market, by geography 2007 – 2014 ($Millions)
31 Global ceramic based bone graft substitutes mixed with calcium phosphate market, by geography 2007 – 2014 ($Millions)
32 Major players and product developments
33 Global allograft based bone graft substitutes market, by geography 2007 – 2014 ($Millions)
34 Major players and product developments
35 Global factors based bone graft substitutes, by geography 2007 – 2014 ($Millions)
36 Major players and product developments
37 Global cell based bone graft substitutes market by geography 2007 – 2014 ($Millions)
38 Major players and product developments
39 Global antibiotic bone cements market, by geography 2007 – 2014 ($Millions)
40 Major players and product developments
41 Global drug eluting stents market, by products 2007 – 2014 ($Millions)
   41a Global drug eluting stents market, by product by thousands of units 2007 – 2014
42 Global drug eluting stents market, by geography 2007 – 2014 ($ Millions)
43 Global coronary stents market, by geography 2007 – 2014 ($Millions)
44 Major players and product developments
45 Global peripheral vascular stent market by geography 2007 – 2014 ($Millions)
46 Global photodynamic therapy market, by products 2007 – 2014 ($Millions)
47 Global photodynamic therapy market, by geography 2007 – 2014 ($Millions)
48 Major players and product developments
49 Global aminolevulinic acid market, by geography 2007 – 2014 ($Millions)
50 Global porfimer sodium market, by geography 2007 – 2014 ($Millions)
51 Major players and product developments
52 Global verteporfin market, by geography 2007 – 2014 ($Millions)
53 Global steroid eluting electrodes market by products 2007 – 2014 ($Millions)
   53a Global steroid eluting electrodes market, by products by thousands of units 2007 – 2014
54 Global steroid eluting electrodes market by geography 2007 – 2014 ($Millions)
55 Major players and product developments
56 Global implancardioverter market, by geography 2007 – 2014 ($Millions)
57 Global deep brain stimulator market, by geography 2007 – 2014 ($Millions)
58 Global closed loop glucose monitor and insulin pump market, by geography 2007 – 2014 ($Millions)
59 Major players and product developments
60 Global cardiovasular treatment market, by applications 2007 – 2014 ($Millions)
61 Global non cardiovascular treatment market, by applications 2007 – 2014 ($Millions)
62 Global urologicaltreatment market, by applications 2007 – 2014 ($Millions)
63 Global bone treatment market, by applications 2007 – 2014 ($Millions)
64 Global antimicrobial applications market 2007 – 2014 ($ Millions)
65 Global cancer treatment market, by applications 2007 – 2014 ($Millions)
66 Global skin care/treatment market, by applications 2007 – 2014 ($Millions)
67 Global ophthalmic tretment market, by applications 2007 – 2014 ($ Millions)
68 Global bone graft substitutes market, by technology 2007 – 2014 ($Millions)
69 Global drug-device combination market 2007 – 2014 ($Millions)
70 U.S. drug-device combination market, by products 2007 – 2014 ($Millions)
   70a U.S. drug-device combination market, by product by thousands of units 2007 – 2014
71 European drug-device combination market, by products 2007 – 2014 ($Millions)
   71a European drug-device combination market, by product by thousands of units 2007 – 2014
72 Asian drug-device combination market, by products 2007 – 2014 ($Millions)
   72a Asian drug-device combination market, by product, by thousands of units 2007-2014
73 3M’s product portfolio
74 3M strategies
75 Abbott laboratories’ product portfolio
76 Abbott laboratories strategies
77 Acrymed’s product portfolio
78 Agion technologies product portfolio
79 Agion technologies, inc. strategies
80 Allosource’s product portfolio
81 Allosource strategies
82 Angiotech pharmaceuticals’ product portfolio
83 Angiotech pharmaceuticals strategies
84 Apatech’s product portfolio
85 Arrow international’s product portfolio
86 Atrium medical’s product portfolio
87 Atrium medical strategies
88 Biomet orthopedics’ product portfolio
89 Biometrix’s product portfolio
90 Biosensors’ product portfolio
91 Biosensors strategies
92 Biotronik’s product portfolio
93 Biotronik strategies
94 Boston scientific’s product portfolio
95 Boston scientific strategies
96 C.R. bard’s product portfolio
97 Biotronik strategies
98 Collagen’s matrix product portfolio
99 Cook critical care’s product portfolio
100 Cook medical’s product portfolio
101 Cook medical strategies
102 Cordis corporation’s product portfolio
103 Corin product portfolio
104 Corin strategies
105 Covalon’s product portfolio
106 Covalon strategies
107 Covidien’s product portfolio
108 Covidien strategies
109 Davol’s product portfolio
110 Depuy orthopaedics’ product portfolio
111 Dusa pharmaceuticals’ product portfolio
112 Dusa pharmaceuticals strategies
113 Edwards lifesciences product portfolio
114 Etex’s product portfolio
115 Etex strategies
116 Ethicon’s product portfolio
117 Exactech’s product portfolio
118 Integra lifesciences product portfolio
119 Integra lifesciences strategies
120 Kiadis pharma’s product portfolio
121 Lifecell corp.’s product portfolio
122 Medtronic’s product portfolio
123 Medtronic strategies
124 Nucryst pharmaceuticals product portfolio
125 Orbusneich co., ltd. product portfolio
126 Organogenesis, inc’s product portfolio
127 Osteotech, inc.’s product portfolio
128 QLT’s product portfolio
129 Smith & nephew’s product portfolio
130 Smith & nephew strategies
131 Spire biomedical’s product portfolio
132 St. jude’s product portfolio
133 St. jude strategies
134 Stryker’s product portfolio
135 Sungwon’s medical product portfolio
136 Synthes product portfolio
137 Tei biosciences product portfolio
138 Vygon’s product portfolio
139 W.L. gore & associates product portfolio
140 W.L. gore & associates strategies
141 Wright medical’s product portfolio
142 Xtent’s product portfolio
143 Zimmer’s product portfolio
144 Zimmer strategies